The narrowing losses and extended cash runway into Q2 2027 reduce near-term dilution risk. Upcoming catalysts include mid-2027 pivotal data from PiNACLE trial supporting a potential BLA filing. Monitor progress in PiNACLE-H2H and LYL273 dose escalation for further de-risking.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 13 $21.25entry
- T+1 · 8mo ago −0.56%α −1.59% · $21.13
- T+5 · 8mo ago −10.02%α −7.91% · $19.12
- T+20 · 7mo ago +16.71%α +13.12% · $24.80
- T+60 · 5mo ago −42.07%α −53.69% · $12.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lyell Immunopharma reported its Q4 and full-year 2025 financial results, highlighted by reduced net losses compared to the prior year, ongoing pivotal trials for ronde-cel in lymphoma, clinical progress with LYL273 in colorectal cancer, and a $50 million equity tranche closing. The company has $247.2 million in cash as of year-end 2025, with runway into Q2 2027.
Key Financial Metrics
Key Facts
- Net loss narrowed to $140.7M in Q4 2025 from $191.9M in Q4 2024; full-year loss decreased to $274.4M from $343.0M in 2024.
- Cash, cash equivalents, and marketable securities were $247.2M as of December 31, 2025, excluding $50M raised in March 2026.
- Patient dosing has commenced in the Phase 3 head-to-head PiNACLE-H2H trial of ronde-cel vs. axi-cel or liso-cel in 2L large B-cell lymphoma.
- Seven new patients treated with LYL273 in mCRC since acquisition, with no dose-limiting toxicity and escalation to Dose Level 3.
- Ronde-cel showed 93% best overall response rate and 76% complete response rate in 29 efficacy-evaluable patients in the 3L+ setting.
- Second $50M tranche of $100M private placement closed in March 2026 after clinical milestone achievement.
- Smital Shah appointed Chief Financial and Business Officer in March 2026.
Financial Impact
Reduced operating expenses and improved cash efficiency: non-GAAP net loss decreased to $33.1M (Q4) and $144.8M (full-year) from $45.9M and $159.5M in 2024. R&D spend decreased on a non-GAAP basis despite LYL273 acquisition costs.
Risk Factors
- High cash burn relative to market cap; future equity offerings likely if trials extend or fail.
- Clinical trial execution risk in large randomized Phase 3 trial (PiNACLE-H2H).
- LYL273 is early-stage with limited data; dose escalation could reveal toxicity.
- Forward-looking statements carry significant uncertainty; no revenue from product candidates yet.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255090 |
Track record
21 reports on LYEL
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers